Cargando…
PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426852/ http://dx.doi.org/10.1097/01.HS9.0000872880.63592.60 |
| _version_ | 1784778771870515200 |
|---|---|
| author | M., RAB M., VAN DIJK J., BOS B., VAN OIRSCHOT J., GERRITS P., KOSINSKI C., KUNG J., JANS E., VAN BEERS L., DANG R., VAN WIJK |
| author_facet | M., RAB M., VAN DIJK J., BOS B., VAN OIRSCHOT J., GERRITS P., KOSINSKI C., KUNG J., JANS E., VAN BEERS L., DANG R., VAN WIJK |
| author_sort | M., RAB |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9426852 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94268522022-08-31 PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS M., RAB M., VAN DIJK J., BOS B., VAN OIRSCHOT J., GERRITS P., KOSINSKI C., KUNG J., JANS E., VAN BEERS L., DANG R., VAN WIJK Hemasphere Pitch Presentations Lippincott Williams & Wilkins 2022-08-16 /pmc/articles/PMC9426852/ http://dx.doi.org/10.1097/01.HS9.0000872880.63592.60 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Pitch Presentations M., RAB M., VAN DIJK J., BOS B., VAN OIRSCHOT J., GERRITS P., KOSINSKI C., KUNG J., JANS E., VAN BEERS L., DANG R., VAN WIJK PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS |
| title | PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS |
| title_full | PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS |
| title_fullStr | PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS |
| title_full_unstemmed | PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS |
| title_short | PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS |
| title_sort | pi-05: pharmacodynamic effects of ag-946, a highly potent novel activator of pyruvate kinase, in ex vivo treatment of red blood cells from sickle cell disease patients |
| topic | Pitch Presentations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426852/ http://dx.doi.org/10.1097/01.HS9.0000872880.63592.60 |
| work_keys_str_mv | AT mrab pi05pharmacodynamiceffectsofag946ahighlypotentnovelactivatorofpyruvatekinaseinexvivotreatmentofredbloodcellsfromsicklecelldiseasepatients AT mvandijk pi05pharmacodynamiceffectsofag946ahighlypotentnovelactivatorofpyruvatekinaseinexvivotreatmentofredbloodcellsfromsicklecelldiseasepatients AT jbos pi05pharmacodynamiceffectsofag946ahighlypotentnovelactivatorofpyruvatekinaseinexvivotreatmentofredbloodcellsfromsicklecelldiseasepatients AT bvanoirschot pi05pharmacodynamiceffectsofag946ahighlypotentnovelactivatorofpyruvatekinaseinexvivotreatmentofredbloodcellsfromsicklecelldiseasepatients AT jgerrits pi05pharmacodynamiceffectsofag946ahighlypotentnovelactivatorofpyruvatekinaseinexvivotreatmentofredbloodcellsfromsicklecelldiseasepatients AT pkosinski pi05pharmacodynamiceffectsofag946ahighlypotentnovelactivatorofpyruvatekinaseinexvivotreatmentofredbloodcellsfromsicklecelldiseasepatients AT ckung pi05pharmacodynamiceffectsofag946ahighlypotentnovelactivatorofpyruvatekinaseinexvivotreatmentofredbloodcellsfromsicklecelldiseasepatients AT jjans pi05pharmacodynamiceffectsofag946ahighlypotentnovelactivatorofpyruvatekinaseinexvivotreatmentofredbloodcellsfromsicklecelldiseasepatients AT evanbeers pi05pharmacodynamiceffectsofag946ahighlypotentnovelactivatorofpyruvatekinaseinexvivotreatmentofredbloodcellsfromsicklecelldiseasepatients AT ldang pi05pharmacodynamiceffectsofag946ahighlypotentnovelactivatorofpyruvatekinaseinexvivotreatmentofredbloodcellsfromsicklecelldiseasepatients AT rvanwijk pi05pharmacodynamiceffectsofag946ahighlypotentnovelactivatorofpyruvatekinaseinexvivotreatmentofredbloodcellsfromsicklecelldiseasepatients |